NCT07573202

Brief Summary

The purpose of this study is to document the incidence of allergic contact dermatitis (ACD) to silk fibroin and 2-octyl cyanoacrylate mesh dressings after open shoulder surgery, to identify differences in clinic utilization for complications related to silk fibroin and 2-octyl cyanoacrylate mesh dressings and to collect patient reported outcome measures (PROMs) related to patient comfort and satisfaction for silk fibroin and 2-octyl cyanoacrylate mesh dressings.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
350

participants targeted

Target at P75+ for not_applicable

Timeline
25mo left

Started Jun 2026

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 1, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 7, 2026

Completed
2 months until next milestone

Study Start

First participant enrolled

June 30, 2026

Expected
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2028

1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 30, 2028

Last Updated

May 7, 2026

Status Verified

May 1, 2026

Enrollment Period

2 years

First QC Date

May 1, 2026

Last Update Submit

May 1, 2026

Conditions

Keywords

silk fibroin (SYLKE)2-octyl cyanoacrylate mesh (Dermabond PRINEO)open shoulder surgery

Outcome Measures

Primary Outcomes (1)

  • Number of participants with allergic contact dermatitis (ACD) to dressings as assessed by clinical examination

    ACD will be diagnosed as erythema, with or without weeping or pruritus, in a geometric border at the surgical site and in the absence of fluctuance or purulence

    at the time of dressing removal, which is about 10-14 days after the operation

Secondary Outcomes (3)

  • Clinic utilization will be defined as the total number of additional patient communications or visits regarding dressings or wound complications

    6 weeks after the operation

  • Patients comfort as assessed by question 6 on the wound experience questionnaire

    2 weeks after the operation

  • Patients satisfaction as assessed by question 7 on the wound experience questionnaire

    2 weeks after the operation

Study Arms (2)

SYLKE dressing

EXPERIMENTAL
Device: silk fibroin (SYLKE)

Dermabond PRINEO dressing

ACTIVE COMPARATOR
Device: 2-octyl cyanoacrylate mesh (Dermabond PRINEO)

Interventions

SYLKE dressing will be placed in a sealed envelope, which will be opened by the operative surgeon during wound closure and placed on the closed wound. 2 week and 6 week postoperative appointments will include a standard postoperative examination that will evaluate and remove the dressing, as well as examine and document a physical examination of the surgical wound.

SYLKE dressing

Dermabond PRINEO dressing will be placed in a sealed envelope, which will be opened by the operative surgeon during wound closure and placed on the closed wound. 2 week and 6 week postoperative appointments will include a standard postoperative examination that will evaluate and remove the dressing, as well as examine and document a physical examination of the surgical wound.

Dermabond PRINEO dressing

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • open shoulder procedure with Dr. James Gregory or Dr. Robert Fullick.

You may not qualify if:

  • Prior documented medical adhesive contact allergy.
  • Negative pressure wound dressings.
  • Any procedure involving a wound problem at the planned surgical site.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The University of Texas Health Science Center at Houston

Houston, Texas, 77030, United States

Location

Study Officials

  • James M Gregory, MD

    The University of Texas Health Science Center, Houston

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

May 1, 2026

First Posted

May 7, 2026

Study Start (Estimated)

June 30, 2026

Primary Completion (Estimated)

June 30, 2028

Study Completion (Estimated)

July 30, 2028

Last Updated

May 7, 2026

Record last verified: 2026-05

Data Sharing

IPD Sharing
Will not share

Locations